The economic burden of bipolar disorderSTIMMEL, Glen L.Psychiatric services (Washington, D.C.). 2004, Vol 55, Num 2, pp 117-118, issn 1075-2730, 2 p.Article

Clinical review of a long-acting, injectable formulation of risperidoneKNOX, Erin Danielle; STIMMEL, Glen L.Clinical therapeutics. 2004, Vol 26, Num 12, pp 1994-2002, issn 0149-2918, 9 p.Article

Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) programJINMEI LI; MCCOMBS, Jeffrey S; STIMMEL, Glen L et al.Journal of affective disorders. 2002, Vol 71, Num 1-3, pp 131-139, issn 0165-0327Article

Counseling patients about sexual issuesSTIMMEL, Glen L; GUTIERREZ, Mary A.Pharmacotherapy. 2006, Vol 26, Num 11, pp 1608-1615, issn 0277-0008, 8 p.Article

Ziprasidone: An atypical antipsychotic Drug for the treatment of schizophreniaSTIMMEL, Glen L; GUTIERREZ, Mary A; LEE, Vivian et al.Clinical therapeutics. 2002, Vol 24, Num 1, pp 21-37, issn 0149-2918Article

Venlafaxine: A 2003 updateGUTIERREZ, Mary A; STIMMEL, Glen L; AISO, Janet Y et al.Clinical therapeutics. 2003, Vol 25, Num 8, pp 2138-2154, issn 0149-2918, 17 p.Article

A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorderMCCOMBS, Jeffrey S; LIZHENG SHI; STIMMEL, Glen L et al.Clinical therapeutics. 2002, Vol 24, Num 11, pp 1939-1959, issn 0149-2918, 21 p.Article